English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Models of Models: A Translational Route for Cancer Treatment and Drug Development

MPS-Authors
/persons/resource/persons50409

Lehrach,  H.
Alacris Theranostics GmbH, Berlin, Germany;
Emeritus Group of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

Fulltext (public)

Ogilvie.pdf
(Publisher version), 345KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Ogilvie, L. A., Kovachev, A., Wierling, C., Lange, B. M. H., & Lehrach, H. (2017). Models of Models: A Translational Route for Cancer Treatment and Drug Development. Frontiers in Oncology, 7: 7:219. doi:10.3389/fonc.2017.00219.


Cite as: http://hdl.handle.net/21.11116/0000-0000-F699-E
Abstract
Every patient and every disease is different. Each patient therefore requires a personalized treatment approach. For technical reasons, a personalized approach is feasible for treatment strategies such as surgery, but not for drug-based therapy or drug development. The development of individual mechanistic models of the disease process in every patient offers the possibility of attaining truly personalized drug-based therapy and prevention. The concept of virtual clinical trials and the integrated use of in silico, in vitro, and in vivo models in preclinical development could lead to significant gains in efficiency and order of magnitude increases in the cost effectiveness of drug development and approval. We have developed mechanistic computational models of large-scale cellular signal transduction networks for prediction of drug effects and functional responses, based on patient-specific multi-level omics profiles. However, a major barrier to the use of such models in a clinical and developmental context is the reliability of predictions. Here we detail how the approach of using "models of models" has the potential to impact cancer treatment and drug development. We describe the iterative refinement process that leverages the flexibility of experimental systems to generate highly dimensional data, which can be used to train and validate computational model parameters and improve model predictions. In this way, highly optimized computational models with robust predictive capacity can be generated. Such models open up a number of opportunities for cancer drug treatment and development, from enhancing the design of experimental studies, reducing costs, and improving animal welfare, to increasing the translational value of results generated.